Tumour Suppressor Mechanisms in the Control of Chromosome Stability: Insights from BRCA2

Overview

Journal Mol Cells

Publisher Elsevier

Specialties Cell Biology
Molecular Biology

Date 2014 Mar 7

PMID 24598993

Citations 14

Authors

Ashok R Venkitaraman

Affiliations

Soon will be listed here.

Abstract

Cancer is unique amongst human diseases in that its cellular manifestations arise and evolve through the acquisition of somatic alterations in the genome. In particular, instability in the number and structure of chromosomes is a near-universal feature of the genomic alterations associated with epithelial cancers, and is triggered by the inactivation of tumour suppressor mechanisms that preserve chromosome integrity in normal cells. The nature of these mechanisms, and how their inactivation promotes carcinogenesis, remains enigmatic. I will review recent work from our laboratory on the tumour suppressor BRCA2 that addresses these issues, focusing on new insights into cancer pathogenesis and therapy that are emerging from improved understanding of the molecular basis of chromosomal instability in BRCA2-deficient cancer cells.

Citing Articles

A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient.

Han Y, Rovella V, Smirnov A, Buonomo O, Mauriello A, Perretta T Cell Death Discov. 2023; 9(1):370.

PMID: 37813891 PMC: 10562433. DOI: 10.1038/s41420-023-01651-3.

Single-Stranded DNA Binding Proteins and Their Identification Using Machine Learning-Based Approaches.

Guo J, Malik F Biomolecules. 2022; 12(9).

PMID: 36139026 PMC: 9496475. DOI: 10.3390/biom12091187.

Expression and clinical significance of NUF2 in kidney renal clear cell carcinoma.

Shan L, Zhu X, Zhang Y, Gu G, Cheng X Transl Androl Urol. 2021; 10(9):3628-3637.

PMID: 34733658 PMC: 8511540. DOI: 10.21037/tau-21-620.

A Link between Replicative Stress, Lamin Proteins, and Inflammation.

Willaume S, Rass E, Fontanilla-Ramirez P, Moussa A, Wanschoor P, Bertrand P Genes (Basel). 2021; 12(4).

PMID: 33918867 PMC: 8070205. DOI: 10.3390/genes12040552.

A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death.

Scott D, Francis-Newton N, Marsh M, Coyne A, Fischer G, Moschetti T Cell Chem Biol. 2021; 28(6):835-847.e5.

PMID: 33662256 PMC: 8219027. DOI: 10.1016/j.chembiol.2021.02.006.

References

Shivji M, Mukund S, Rajendra E, Chen S, Short J, Savill J . The BRC repeats of human BRCA2 differentially regulate RAD51 binding on single- versus double-stranded DNA to stimulate strand exchange. Proc Natl Acad Sci U S A. 2009; 106(32):13254-9. PMC: 2714763. DOI: 10.1073/pnas.0906208106. View

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

Caldas C, Kern S . K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol. 1995; 18(1):1-6. DOI: 10.1007/BF02825415. View

Menzel T, Nahse-Kumpf V, Nedergaard Kousholt A, Klein D, Lund-Andersen C, Lees M . A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance. EMBO Rep. 2011; 12(7):705-12. PMC: 3128973. DOI: 10.1038/embor.2011.99. View

Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. DOI: 10.1038/nature03443. View

Skoulidis F, Cassidy L, Pisupati V, Jonasson J, Bjarnason H, Eyfjord J . Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell. 2010; 18(5):499-509. DOI: 10.1016/j.ccr.2010.10.015. View

Couch F, Johnson M, Rabe K, Brune K, de Andrade M, Goggins M . The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(2):342-6. DOI: 10.1158/1055-9965.EPI-06-0783. View

Hezel A, Kimmelman A, Stanger B, Bardeesy N, DePinho R . Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006; 20(10):1218-49. DOI: 10.1101/gad.1415606. View

Jeyasekharan A, Liu Y, Hattori H, Pisupati V, Jonsdottir A, Rajendra E . A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization. Nat Struct Mol Biol. 2013; 20(10):1191-8. PMC: 3796201. DOI: 10.1038/nsmb.2666. View

10.

Choi E, Park P, Lee H, Lee Y, Kang G, Lee J . BRCA2 fine-tunes the spindle assembly checkpoint through reinforcement of BubR1 acetylation. Dev Cell. 2012; 22(2):295-308. DOI: 10.1016/j.devcel.2012.01.009. View

11.

Ayoub N, Rajendra E, Su X, Jeyasekharan A, Mahen R, Venkitaraman A . The carboxyl terminus of Brca2 links the disassembly of Rad51 complexes to mitotic entry. Curr Biol. 2009; 19(13):1075-85. PMC: 2719694. DOI: 10.1016/j.cub.2009.05.057. View

12.

Parkin D, Bray F, Devesa S . Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37 Suppl 8:S4-66. DOI: 10.1016/s0959-8049(01)00267-2. View

13.

Redston M, Caldas C, Seymour A, Hruban R, Da Costa L, Yeo C . p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994; 54(11):3025-33. View

14.

Tutt A, van Oostrom C, Ross G, van Steeg H, Ashworth A . Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation. EMBO Rep. 2002; 3(3):255-60. PMC: 1084010. DOI: 10.1093/embo-reports/kvf037. View

15.

Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A . Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001; 29(4):418-25. DOI: 10.1038/ng747. View

16.

Willems-Jones A, Kavanagh L, Clouston D, Bolton D, Fox S, Thorne H . High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer. BJU Int. 2012; 110(11 Pt C):E1181-6. DOI: 10.1111/j.1464-410X.2012.11519.x. View

17.

Gretarsdottir S, Thorlacius S, Valgardsdottir R, Gudlaugsdottir S, Sigurdsson S, Steinarsdottir M . BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res. 1998; 58(5):859-62. View

18.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

19.

Venkitaraman A . Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002; 108(2):171-82. DOI: 10.1016/s0092-8674(02)00615-3. View

20.

Yu V, Koehler M, Steinlein C, Schmid M, Hanakahi L, van Gool A . Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev. 2000; 14(11):1400-6. PMC: 316655. View